News Releases

June 29, 2018
Neon Therapeutics Announces Closing of Initial Public Offering

CAMBRIDGE, Mass. , June 29, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the closing of its initial public offering of 6,250,000 shares of common stock at a public offering price of

Additional Formats
June 26, 2018
Neon Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass. , June 26, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price
Additional Formats
May 8, 2018
Neon Therapeutics Announces First Patient Treated in Clinical Trial Evaluating Personal Cancer Vaccine NEO-PV-01 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy
Cambridge, Mass., May 8, 2018  –  Neon Therapeutics , a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that it has treated the first patient in a clinical trial evaluating its proprietary personal neoantigen vaccine, NEO-PV-01, in combination with
Additional Formats